Thayse Bruggemann, PhD
(She/Her/Hers)
Rank
Instructor
Department
Medicine
Pulmonary and Critical Care
Authors
Thayse R. Brüggemann, PhD*, Hong Yong Peh, PhD, Luciana P. Tavares PhD, Julie Nijmeh, PhD, Ashley E. Shay, PhD, Rafael M. Rezende, PhD, Toby B. Lanser, Charles N. Serhan, PhD, Bruce D. Levy, MD
Principal Investigator
Bruce D. Levy
Twitter / Website
Twitter: @BDLevyLab
Categories
Eosinophils (Eos) are key players in immune responses, particularly during allergic lung inflammation. In a murine model, two Eos subsets were identified based on CD101 expression: CD101low and CD101high. CD101low Eos are present in the lungs both at baseline and during inflammation, primarily residing in the lung’s vascular niche. CD101high Eos, which appear only during inflammation, are mainly found in the bronchoalveolar space. Following allergen exposure, CD101low Eos increase their activation, migrate into the lung interstitium and bronchoalveolar space, and convert into CD101high Eos, a process partially driven by IL-5. Resolvin D2 (RvD2), a pro-resolving mediator, reduces the overall number of Eos, particularly CD101high Eos in bronchoalveolar lavage fluid. RvD2 achieves this by decreasing IL-5-dependent recruitment of CD101low Eos and inhibiting their conversion to CD101high Eos. These findings reveal that Eos are a heterogeneous population with distinct activation states and that RvD2 plays a critical role in resolving eosinophilic inflammation, suggesting its potential as a therapeutic strategy.